Podcast appearances and mentions of William K Oh

Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Featuring perspectives from Dr Rahul Aggarwal, Ms Monica Averia, Ms Kathleen D Burns and Dr William K Oh, including the following topics: Introduction: Overview of Prostate Cancer (0:00) Recent Advances in the Treatment of Nonmetastatic Prostate Cancer (8:36) Treatment Approaches for Metastatic Hormone-Sensitive Prostate Cancer (30:01) Current Role of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (47:41) Current and Future Role of Radiopharmaceuticals in mCRPC (1:09:57) NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics: Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00) Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14) CME information and select publications

Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28) Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39) Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44) Data surrounding adjuvant immunotherapy for MIBC (38:07) Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44) Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06) Implementation of emerging data in the treatment landscape of UC (41:56) CME information and select publications

Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. CME information and select publications here.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and multiple myeloma. Featuring perspectives from Drs Arjun Balar, Johanna Bendell, Axel Grothey, Brad S Kahl, Shaji K Kumar, Kathleen Moore, Loretta Nastoupil, William K Oh, David M O'Malley, Robert Z Orlowski, Hope S Rugo, Gregory J Riely, David R Spigel and Sara M Tolaney, moderated by Neil Love, MD.

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and multiple myeloma. Featuring perspectives from Drs Arjun Balar, Johanna Bendell, Axel Grothey, Brad S Kahl, Shaji K Kumar, Kathleen Moore, Loretta Nastoupil, William K Oh, David M O'Malley, Robert Z Orlowski, Hope S Rugo, Gregory J Riely, David R Spigel and Sara M Tolaney, moderated by Neil Love, MD.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

COVID-19 and Oncology Care: Interviews and Presentations with 4 Investigators Discussing the Impact of the Pandemic on Lung, Breast, Gastrointestinal and Genitourinary Cancers. Featuring perspectives from Drs Tanios Bekaii-Saab, Stephen V Liu, William K Oh, and Tiffany A Traina moderated by Neil Love, MD. Produced by Research To Practice.

COVID-19 and Oncology Care: Interviews and Presentations with 4 Investigators Discussing the Impact of the Pandemic on Lung, Breast, Gastrointestinal and Genitourinary Cancers. Featuring perspectives from Drs Tanios Bekaii-Saab, Stephen V Liu, William K Oh, and Tiffany A Traina moderated by Neil Love, MD. Produced by Research To Practice.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.

William K. Oh, M.D. Division of Hematology and Medical Oncology The Tisch Cancer Institute Mount Sinai School of Medicine One Gustave L. Levy Place – Box 1079 New York, NY 10029

William K. Oh, MD Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics Chief of the Division of Hematology and Medical Oncology, Mount Sinai School of Medicine  Co-Director of the Prostate Cancer Program, Associate Director for Clinical Research for The Tisch Cancer Institute in 2009.